Latest Financial Results
Q3 2022
Quarter Ended Sep 30, 2022
Sign up for Email Alerts
Sign up todayStock Information
Syros Pharmaceuticals, Inc.
Symbol
Nasdaq: SYRSPrice
Change
Volume
52 week Low/High
Day Low/High
Company Overview
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including tamibarotene (formerly SY-1425), a first-in-class oral selective RARĪ± agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia, SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia, and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.
Latest Presentation
IR Contact Information
Investor Relations
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations
khunady@syros.com
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com
Transfer Agent
Computershare Trust Company, N.A.